[Aerosolized iloprost therapy in an infant with chronic pulmonary hypertension after a neonatal arterial switch

Related Experiment Video

Updated: Aug 14, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

V Lambert1, A Serraf, P Durand

  • 1Centre chirurgical Marie-Lannelongue, 133, avenue de la Résistance, 92350 Le-Plessis-Robinson, France. vlambert@ccml.com

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|January 5, 2002
PubMed

Insights

Inhaled iloprost offers a promising alternative for treating pediatric chronic pulmonary hypertension, avoiding complications associated with long-term venous prostacyclin therapy. This approach improved a patient's condition and quality of life over nine months.

Area of Science:

  • Pediatric Cardiology
  • Pulmonary Hypertension Management
  • Respiratory Medicine

Background:

  • Chronic pulmonary hypertension in children often requires long-term venous prostacyclin therapy, which carries risks of severe complications.
  • Inhaled iloprost has shown preliminary success in adult patients with pulmonary hypertension.

Observation:

  • A case report details the successful use of aerosolized iloprost in an infant with pulmonary hypertension and right ventricular failure post-arterial switch operation.
  • The infant received treatment for nine months.

Findings:

  • Hemodynamic and functional status significantly improved during the nine-month treatment period.
  • The infant experienced a satisfactory quality of life while at home.

Implications:

  • Aerosolized iloprost may represent a viable alternative to intravenous prostacyclin therapy for pediatric chronic pulmonary hypertension.
  • Further research and clinical studies are warranted to validate these findings and support broader adoption.
Abstract

More Related Videos

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP06:55

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP

Published on: February 14, 2022

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...